Author:
Jha Prerana,Trivedi Vaishakhi,Shah Minit,George Irene A.,Kulkarni Pooja Mahesh,Sharma Neha,Ramachandran Venkataramanan,Noronha Vanita,Prabhash Kumar,Kumar Prashant
Reference21 articles.
1. Clinicopathological profile of lung cancer at a tertiary care center;Dattatreya;Indian J. Cancer,2018
2. Clinical management of stage III non-small cell lung cancer in India: an expert consensus statement;Batra;Asia Pac. J. Clin. Oncol.,2023
3. Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study;Gijtenbeek;Lancet Reg. Health Eur.,2023
4. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol.,2016
5. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial;Wu;Lancet Oncol.,2017